MedTrace Logo

PE PREMIER CHINA CLINICAL TRIAL

NCT02230254 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2022-05-12

Study results available
· View outcomes & findings →

Summary

PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

Conditions

Interventions

DEVICE

Percutaneous coronary intervention PROMUS PREMIER

PROMUS PREMIER

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Jian'an Wang, Doctor · 2nd affiliated hospital of Zhejiang University College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-09
Primary Completion
2014-06-22
Completion
2015-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02230254 on ClinicalTrials.gov